Free Twice-Weekly Pharma Manufacturing Newsletter Stay current on Biopharma Packing & Security, Supply Chain Software & Systems, and Contract Manufacturing with a twice-weekly update sent straight to your Inbox. Join more than 30,000 pharma professionals who subscribe to FiercePharmaManufacturing for FREE!
Teva Pharamaceuticals ($TEVA) is discovering size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging the jumbo-sized vials it used for its anesthetic propofol encouraged re-use and led to colonoscopy patients developing hepatitis C. The company no longer makes the drug. The money will settle about 120 lawsuits, mostly from patients of a Nevada colonoscopy center. It will also settle a case in which it faced a $500 million jury award. Story
FiercePharmaManufacturing provides must-know news and insight on the hardware and software tools used to automate pharmaceutical manufacturing. Click here to get your free twice weekly email briefing today!